Ryan Specialty Holdings (RYAN) PT Lowered From $52 to $45 at Barclays Amid AI Disruption Concerns

Core Insights - Ryan Specialty Holdings, Inc. (NYSE:RYAN) is identified as one of the most oversold stocks in the insurance sector, according to analysts [1] Financial Performance - For Q4 2025, Ryan Specialty reported a 13.2% year-over-year increase in sales, reaching $751.2 million, driven by acquisitions, higher contingent commissions, and 6.6% organic revenue growth [3] - Despite the sales increase, net income fell by 26.6% to $31.2 million due to higher operational and interest costs [3] - Adjusted net income for the year rose by 0.5% to $124 million, while adjusted EBITDAC increased by 2.9% to $222.3 million [4] - Total revenue for the year grew by 21.3% to $3.05 billion, with adjusted diluted EPS increasing by 9.5% to $1.96, indicating sustained growth in the specialty insurance platform [4] Market Sentiment - Barclays has lowered the price target for RYAN from $52 to $45, maintaining an Overweight rating, citing concerns over AI-related disruptions in the insurance brokerage industry, although they believe the current valuation is excessive [2][8] - The firm argues that current valuations reflect slower growth expectations while underestimating the durability of the brokerage model and the potential for AI to enhance margins and efficiency [2]